Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical–serological–pathological classification
Authors' conclusion
Stratification combining clinical, serological and pathological features could distinguish phenotypes and prognosis of IMNM.
Study context
- Population
- Patients with immune-mediated necrotizing myopathy (IMNM) meeting the 2018 European Neuromuscular Center criteria (62 anti-SRP, 32 anti-HMGCR-positive, 44 myositis-specific antibody-negative)
- Participants
- 138 patients
- Exposure
- Clusters 1, 2 and 3 of IMNM defined by clustering analysis
- Cluster 1n = 35
- Cluster 2n = 79
- Cluster 3n = 24
- Outcome
- Remission and relapse (time-to-remission and relapse-free time)
Methodological detailsclustering analysis based on clinical, serological and pathological parameters, follow-up
- Clustering analysis based on clinical, serological and pathological parameters
- Follow-up
Main finding
As reported in the abstract
Time-to-remission, median survival time
Observational data: associations, not effects.
Further findings
Relapse-free time, median remission time
Relapse-free time, median remission time
- Cluster 3 had shorter relapse-free time than clusters 1 and 2
Predictors of time to remission
- Age of onset >55 years, more regeneration of muscle fibres, more CD4+ T infiltration and membrane attack complex deposition had more favourable outcomes regarding time to achieving remission
Original publication
Distinct phenotype and prognosis of immune-mediated necrotizing myopathy based on clinical–serological–pathological classification. Rheumatology (Oxford). Published 19 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →